Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tetanus+ pnemococcal vaccines alone · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | ACTIVE_COMPARATOR | - |
| Group 3 | ACTIVE_COMPARATOR | - |
| Group 4 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Tetanus + pnemococcal vaccines alone | DRUG | 0 mg + vaccines, Single dose, 28 days. |
| Abatacept + vaccines | DRUG | Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days. |
Inclusion Criteria: * Healthy Subjects * Body Weight between 60 and 100 kg. * Males and Females must be using adequate contraceptive methods during study and for 10 weeks after dose of study mediciation. Exclusion Criteria: * Females who are prgnant or breastfeeding * History of autoimmune disord...
Top 20 of 28 competitors
Tetanus+ pnemococcal vaccines alone is a small molecule being studied for use in Rheumatoid Arthritis. It is currently in Phase 1 clinical development as an investigational therapy. The drug is being developed by Bristol-Myers Squibb Company, and it is not yet approved for any use.
Tetanus+ pnemococcal vaccines alone is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical research on this drug for the treatment of Rheumatoid Arthritis. The drug is currently in Phase 1 development.
Tetanus+ pnemococcal vaccines alone is in Phase 1 clinical development. It is an investigational drug being studied for Rheumatoid Arthritis. The drug has completed one Phase 1 trial, and it is not yet approved by regulatory authorities.
Tetanus+ pnemococcal vaccines alone has one completed clinical trial, NCT00279734, titled 'Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers'. This Phase 1 study enrolled 80 participants in the United States and was an active-controlled, randomized trial. The trial is now completed.
Tetanus+ pnemococcal vaccines alone is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Rheumatoid Arthritis. The drug has completed one clinical trial, but it remains in the early stages of research and has not been approved for any medical use.